Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Avita Medical (RCEL) to $11 from $12 and keeps a Neutral rating on the shares. The firm notes Avita released full Q4 results which came in line with their preannouncement. Guidance was also reiterated, with the company expecting $100M- $106M for FY25. Guidance is fairly set, in Piper’s view, bolstered by the further expansion into trauma, and new products.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue